Lung cancer is the leading cause of cancer deaths worldwide. Therefore, assessing the potential of established biomarkers for predicting the outcome and the response to specific therapies is important to improve the prognosis of patients with non-small cell lung cancer (NSCLC). Tumour staging and performance status are currently the most powerful prognostic predictors in patients with NSCLC ([@bib2]). Recent large-scale studies demonstrated that sex, smoking history, and histology could affect the prognosis after treatment in patients with NSCLC, especially in adenocarcinoma (AC) ([@bib13]; [@bib21]; [@bib17]). Performance status and disease staging are generally known factors associated with prognosis after treatment.

ASC amino-acid transporter 2 (ASCT2) is a Na^+^-dependent transporter responsible for the transport of neutral amino acids, including glutamine, leucine, and isoleucine ([@bib14]). It is the major glutamine transporter in human hepatoma cells ([@bib5]), and has a role in tumour growth and the proliferation of cancer cells ([@bib4]). It is highly expressed in various malignancies, including hepatocellular carcinoma and colorectal or prostate cancer, and its expression is closely associated with tumour aggressiveness and prognosis in colorectal or prostate cancer ([@bib25]; [@bib18]; [@bib5]). It provides cancer cells with essential amino acids for protein synthesis, and it coordinates tumour cell growth through the activation of mammalian target of rapamycin (mTOR) ([@bib5]). Glutamine promotes cancer cell proliferation and has a high affinity for ASCT2 ([@bib4]; [@bib5]). Amino-acid transporters are essential for the growth and survival of tumour cells, and L-type amino-acid transporter 1 (LAT1) also has a crucial role in the development and proliferation of transformed cells ([@bib12]; [@bib27]; [@bib9], [@bib11]). It is an L-type amino-acid transporter that transports large neutral amino acids, such as leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan, methionine, and histidine ([@bib12]; [@bib27]). It requires a covalent association with the heavy chain of 4F2 cell-surface antigen (CD98) for its functional expression and localisation in the plasma membrane ([@bib12]; [@bib27]). Recent studies have focussed on ASCT2 and LAT1, which are highly expressed in cancer cells ([@bib4]). The overexpression of LAT1 may be a significant predictor of poor prognosis, and it is closely linked to the aggressiveness and metastasis of various human neoplasms ([@bib23]; [@bib22]; [@bib9], [@bib11]; [@bib24]; [@bib7]; [@bib6]). Although the clinical importance of LAT1 expression in cancer cells is understood, the clinicopathological significance of ASCT2 expression in human neoplasms remains unclear. We therefore conducted a clinicopathological study to investigate the expression of ASCT2 in tissue specimens of resected NSCLC. The aim of our study was to clarify whether the expression of ASCT2 was closely associated with the outcome after treatment and to explore the relationship between ASCT2 and clinical characteristics. In addition, the correlation between ASCT2 expression and CD98, the Ki-67 labelling index (LI), microvessel density (MVD) (determined by CD34), and the phosphorylation of mTOR (p-mTOR) was assessed.

Materials and methods
=====================

Patients
--------

We analysed 111 consecutive patients with NSCLC who underwent resection either by lobectomy or pneumonectomy with mediastinal lymph-node dissection at Nishigunma National Hospital (NGH, Shibukawa, Japan) between July 2007 and January 2010. Of these patients, 7 were excluded from further analysis because tissue specimens were not available; thus, 104 patients were enrolled in the study. Postoperative adjuvant chemotherapy with platinum-based regimens, S-1 (Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) and oral administration of tegafur (a fluorouracil derivative drug) were administered to 19, 1, and 12 patients, respectively. No chemotherapy or radiotherapy before surgery was performed on any patient. The study protocol was approved by the institutional review board. The tumour specimens were histologically classified according to World Health Organisation criteria. The stages of pathological tumour-node-metastasis were established using the International System for Staging Lung Cancer adopted by the American Joint Committee on Cancer and the Union Internationale Centre le Cancer ([@bib20]). The day of surgery was considered to be the first day after surgery. The follow-up duration ranged from 139 to 2118 days (median, 1362 days).

For validation, we analysed an independent series of patients with NSCLC who underwent complete resection of the primary lung tumour with mediastinal lymph-node dissection at Gunma University Hospital (GUH, Maebashi, Japan) between June 2003 and June 2008. The median follow-up period was 1932 days (range, 160--3765 days).

Immunohistochemical staining
----------------------------

The protocol used for immunohistochemistry (IHC) is described elsewhere ([@bib9], [@bib11]). An oligopeptide (RDSKGLAAAEPTAN), corresponding to amino acids 7--20 of ASCT2 (1 : 300 dilution), was used to synthesise rabbit polyclonal antibodies, as described previously ([@bib1]). The N-terminal cysteine residue was used for conjugation to keyhole limpet haemocyanin. The antiserum was affinity purified as described previously ([@bib3]), and the specificity was confirmed ([Supplementary Procedures](#sup1){ref-type="supplementary-material"}). Briefly, HEK293T cells were transfected with a plasmid encoding ASCT2 or empty vector control. Crude membrane fractions were isolated, separated by SDS--PAGE, and analysed by western blotting as described by [@bib15]. Immunohistochemistry was performed on paraffin sections using the polymer peroxidase method (Histofine Simple Stain MAX PO (MULTI) kit; Nichirei Corp., Tokyo, Japan). Briefly, deparaffinised and rehydrated sections were treated with 0.3% hydrogen peroxide (H~2~O~2~) in methanol for 30 min to block endogenous peroxidase activity. To expose the antigens, sections were autoclaved in ethylenediaminetetraacetic acid (pH 8.0) for 5 min and cooled for 30 min. After rinsing in phosphate-buffered saline, the sections were incubated with affinity-purified anti-ASCT2 antibodies (1 : 300) overnight followed by immunohistochemical staining with a Histofine Simple Stain MAX PO (MULTI) kit (Nichirei Corp.). The peroxidase reaction was carried out using 0.02% 3,3′-diaminobenzidine tetrahydrochloride and 0.01% H~2~O~2~ in 0.05 [M]{.smallcaps} Tris--HCl (pH 7.4). Negative control tissue sections were stained as described above, except that the primary antibody was omitted.

Anti-CD98 is an affinity-purified rabbit polyclonal antibody (1 : 100 dilution; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) raised against a C-terminal peptide of human CD98. ASC amino-acid transporter 2 and CD98 staining was considered as positive only if distinct membrane staining was detected. The ASCT2 and CD98 expression scores were assessed by the extent of staining as follows: 1, ⩽10% of the tumour area stained; 2, 11--25% 3, 26--50% and 4, ⩾51% stained. Those tumours with a score of \>2 were considered to have a high level of expression.

Mouse monoclonal antibodies against CD34 (1 : 800 dilution; Nichirei Corp.) and Ki-67 (1 : 40; Dako, Glostrup, Denmark), and a rabbit monoclonal antibody against p-mTOR (1 : 80; Cell Signaling Technology, Danvers, MA, USA) were also used. The number of CD34-positive vessels was counted in four randomly selected regions in a × 400 field (0.26 mm^2^ field area). The MVD was defined as the mean number of microvessels per 0.26 mm^2^ field area, and tumours in which the number of stained tumour cells was greater than the median were defined as high expressors. For Ki-67, epithelial cells with nuclear staining of any intensity were considered to be positive. Approximately 1000 nuclei were counted on each slide, and the proliferative activity was assessed as the percentage of Ki-67-stained nuclei (Ki-67 LI) in each sample. The median Ki-67 LI was evaluated, and tumours with an LI greater than the median were considered to be positive. For p-mTOR, a semiquantitative scoring method was used: 1, \<10% 2, 10--25% 3, 25--50% and 4, ⩾51% of positive cells. Those tumours with a staining score of \>3 were considered to be strongly stained ([@bib9], [@bib11]). All sections were independently assessed using light microscopy in a blinded manner by at least two of the authors.

Statistical analysis
--------------------

*P*-values\<0.05 were used to indicate a statistically significant difference. Fisher\'s exact test was used to examine the association between two categorical variables. The correlation between different variables was analysed using the non-parametric Spearman\'s rank test. ASC amino-acid transporter 2 expression score was correlated with other immunohistochemical measurements and clinical variables. Since the sample size of NGH was not enough to do multivariate analysis using many prognostic variables; sex, smoking, stage, and histology which are known factors as described above were selected for the analysis. We added ASCT2 to these variables, and multivariate analysis was performed. In GUH cohort, we did multivariate analysis using the same prognostic variables.

Elderly patients were defined as more than 65 years old, and an ever smoker was defined as someone who had smoked at least 100 cigarettes in his lifetime. Disease staging was divided into two groups; stage I or II (early disease) and stage III or IV (advanced disease). The Kaplan--Meier method was used to estimate survival as a function of time, and survival differences were analysed by the log-rank test. Overall survival (OS) was determined as the time from tumour resection to death from any cause. Progression-free survival (PFS) was defined as the time between tumour resection and the first disease progression or death. Multivariate analyses were performed using a stepwise Cox proportional hazards model to identify independent prognostic factors. Statistical analyses were performed using JMP 8 for Windows (SAS Institute Inc., Cary, NC, USA).

Results
=======

Immunohistochemical analysis and clinicopathological features
-------------------------------------------------------------

One hundred and four primary lung cancer lesions were analysed by IHC. [Figure 1](#fig1){ref-type="fig"} shows representative staining for ASCT2. Expression of ASCT2 was detected in carcinoma cells in tumour tissues, and it was localised predominantly on the plasma membrane. All positive cells showed strong membrane staining. High levels of ASCT2 and CD98 expression were observed in 63% (66 out of 104) and 55% (55 out of 104) of the tumours, respectively. When staining was correlated with histological type, a statistically significant difference in ASCT2 staining was observed between patients with AC (55%: 36 out of 66) and non-AC (79%: 30 out of 38) (*P*=0.019). The median number of CD34-positive vessels was 16 (range, 1--41); thus, 16 was chosen as the cutoff to define a high expression level. The median Ki-67 LI was 17% (range, 1--82), so 17% was selected to define high-level expression. High levels of expression of CD34 and Ki-67 LI were detected in 45% (47 out of 104) and 44% (46 out of 104) of the tumours, respectively. A total of 39% (41 out of 104) of the tumours exhibited high-level expression of p-mTOR.

The clinicopathological features of the patients are shown in [Table 1](#tbl1){ref-type="table"}. In the NGH cohort, 28 squamous cell carcinomas (SQCs), 6 large cell carcinomas, and 4 NSCLCs were detected in those patients without AC. In the GUH cohort, all non-AC patients presented with SQC, and the positive expression of ASCT2 was significantly higher in SQC compared with AC (70% *vs* 40%, *P*\<0.001). A statistically significant difference in lymphatic permeation, vascular invasion, and ASCT2, CD98, and p-mTOR staining was observed between the NGH and GUH cohorts.

Patient characteristics based on ASCT2 expression
-------------------------------------------------

[Table 2](#tbl2){ref-type="table"} shows the characteristics of the tumours in the NGH cohort. In all patients (*n*=104), positive ASCT2 expression was significantly associated with being male, having an advanced-stage tumour, T factor, lymph-node metastasis, non-AC, lymphatic permeation, vascular invasion, CD98, Ki-67 LI, and MVD (assessed by CD34 staining). Positive histological staining for ASCT2 in the AC patients was significantly associated with the above variables in addition to p-mTOR, but only with Ki-67 LI in the non-AC patients.

Correlation between ASCT2 expression and different variables
------------------------------------------------------------

On the basis of Spearman\'s rank correlation, ASCT2 was significantly correlated with CD98 (*r*=0.455, *P*\<0.001), Ki-67 (*r*=0.413, *P*\<0.001), MVD (*r*=0.482, *P*\<0.001), and p-mTOR (*r*=0.148, *P*=0.133) in all patients (*n*=104) from the NGH cohort ([Supplementary Table A1](#sup1){ref-type="supplementary-material"}). There was also a close correlation with p-mTOR in the AC patients, but not in the non-AC patients. We also validated the correlation between ASCT2 expression and these markers in the GUH cohort (*n*=204). Consistent with the NGH cohort, ASCT2 expression was positively correlated with CD98 (*r*=0.425, *P*\<0.001), Ki-67 (*r*=0.475, *P*\<0.001), CD34 (*r*=0.496, *P*\<0.001), and p-mTOR (*r*=0.140, *P*=0.045). Expression of ASCT2 was significantly correlated with CD98, Ki-67, MVD, and mTOR in AC patients (*n*=142), and with p-mTOR and MVD in non-AC (*n*=62) subjects.

Patient mortality
-----------------

In the NGH cohort, the 5-year survival rate and median survival time (MST) for all patients were 51% and not reached, respectively. The results of univariate and multivariate analyses are shown in [Table 3](#tbl3){ref-type="table"}, whereas [Figure 2](#fig2){ref-type="fig"} shows the Kaplan--Meier survival curve of patients with positive and negative ASCT2 expression. Patient survival was significantly associated with sex, smoking history, disease stage, histology, lymphatic permeation, vascular invasion, ASCT2, and Ki-67 LI, as assessed by a univariate analysis. A multivariate analysis confirmed that disease stage and ASCT2 were independent prognostic factors for poor PFS and OS. Expression of ASCT2 was also an independent prognostic indicator for poor outcome in patients with AC.

We next sought to validate the association between ASCT2 expression and survival in the GUH cohort. In the validation cohort (GUH series), the 5-year survival rate and MST for all patients were 69% and 3491 days, respectively. We compared the OS after surgery between the NGH and GUH cohorts, and found that the OS in the GUH cohort was significantly longer than in the NGH cohort (*P*=0.007). There was also a (nearly significant) association between positive ASCT2 expression and poor outcome ([Figure 2](#fig2){ref-type="fig"}; [Table 4](#tbl4){ref-type="table"}). In GUH cohort, we did multivariate analysis using the same prognostic variables in NGH cohort. A multivariate analysis indicated that disease stage was an independent prognostic factor for poor outcome in all patients with NSCLC ([Table 4](#tbl4){ref-type="table"}). Survival was then examined in relation to histological sub-type. In patients with AC, tumour stage and ASCT2 expression were independent predictors of poor OS in a multivariate analysis ([Table 5](#tbl5){ref-type="table"}). In contrast, ASCT2 expression was not associated with poor prognosis in patients with SQC.

Discussion
==========

This is the first report to evaluate the prognostic significance of ASCT2 expression in patients with surgically resected NSCLC. Our data clearly demonstrate that ASCT2 expression was an independent prognostic marker for poor outcome after surgery in patients with NSCLC, particularly AC. Although the expression of ASCT2 was increased significantly in non-AC patients compared with AC patients, ASCT2 in AC patients was more closely associated with disease stage, lymphatic permeation, vascular invasion, CD98, cell proliferation, angiogenesis, and mTOR phosphorylation. Moreover, two independent cohorts demonstrated that ASCT2 was an independent predictor of poor outcome in AC patients. Our validated data suggest that ASCT2 has an important role in the aggressiveness and metastasis of lung cancer, particularly AC.

Only two previous studies reported enhanced expression of ASCT2 in primary human colorectal AC and prostate cancer, suggesting a close relationship between its expression and poor prognosis ([@bib25]; [@bib18]). Therefore, further study is warranted to investigate the clinical significance of ASCT2 expression in other human cancers. Our study focussed on the clinicopathological significance of ASCT2 expression in patients with lung cancer. Importantly, our study included validating data from an independent cohort, and evaluated the expression and activation of the mTOR signalling pathway, which is related to protein synthesis. Previously, we demonstrated that LAT1 is required for the upregulation of mTOR in lung cancer, which was supported by *in vitro* and *in vivo* data ([@bib8]; [@bib10]). [@bib5] reported that LAT1 provides essential amino acids for tumour cell growth via mTOR-stimulated translation, and that ASCT2 maintains the cytoplasmic amino-acid pool necessary to promote LAT1 function. Therefore, they demonstrated that both LAT1 and ASCT2 are highly expressed in human cancers, and that there is reciprocal regulation among LAT1, ASCT2, and mTOR. Recent studies demonstrated that the inhibition of amino-acid transporters reduces the p-mTOR, p70 ribosomal S6 kinase, and 4E-binding protein-1. This leads to the induction of apoptosis by depleting the intracellular amino acids required for cancer growth, and induces a cell-cycle arrest at G1 phase ([@bib19]; [@bib26]; [@bib8]; [@bib16]). Because the p-mTOR is closely related to the survival and metastasis of cancer cells, the inhibition of amino-acid transporters such as LAT1 or ASCT2 may suppress tumour growth by decreasing mTOR phosphorylation. However, additional studies are needed to investigate the mechanism by which the inhibition of ASCT2 expression inhibits tumour growth.

We found that ASCT2 could be a pathological marker for predicting poor outcome after surgery, and that it was closely associated with tumour cell proliferation and angiogenesis in patients with AC, but not in non-AC patients (predominantly SQC). However, the reasons for the differential effects and levels of ASCT2 protein expression between AC and non-AC patients remain unclear. Expression of LAT1 is significantly higher in patients with SQC than in those with AC ([@bib9]). The expression of ASCT2 analysed by histological sub-type is similar to that of LAT1 ([@bib9]). In our study, ASCT2 seemed to have an important role in tumour cell proliferation and angiogenesis in AC patients, suggesting a close relationship between ASCT2 expression and prognosis. However, little is known about the clinical significance of the expression pattern of ASCT2 in human tumour tissues. Therefore, it is necessary to investigate ASCT2 expression in various types of cancer using human cancer specimens. Presently, clinicopathological studies of ASCT2 expression are ongoing in gastrointestinal cancer, hepatobiliary cancer, multiple myeloma, ovarian tumours, and breast cancer.

There are several limitations to our study. First, the number of non-AC patients included was small, and the histological distribution of non-AC disease was different between the NGH and GUH cohorts, which may have biased our results. The frequency of SQC patients was significantly higher in the GUH cohort (100%, 62 out of 62) than in the NGH cohort (74%, 28 out of 38) (*P*\<0.01). However, a survival analysis of the non-AC patients seemed to give comparable results in the two cohorts. Second, the frequency of ASCT2 expression in the GUH cohort was significantly lower than in the NGH cohort. Therefore, tumour aggressiveness and prognosis after surgery may be different between these cohorts. In addition, there was a significant difference in lymphatic permeation, vascular invasion, and biomarker expression (CD98 and p-mTOR) between the NGH and GUH cohorts. Although we cannot describe the detailed reason for these differences, the tumour characteristics may be more aggressive in NGH than in GUH, considering that the expression of ASCT2 has a significant relationship with lymphatic permeation, vascular invasion, CD98, and p-mTOR. The present study showed that the expression of ASCT2 was closely associated with lymphatic permeation, vascular invasion, and cell proliferation (Ki-67). Therefore, these factors were excluded from the multivariate analysis to assess ASCT2 as an independent prognostic factor and also to resolve confounding issue. Finally, median survival was not reached for the NGH cohort. In this cohort, five patients were lost to follow-up. The NGH cohort may have a potential for selection bias, because of the issues with loss to follow-up in this cohort. Moreover, the sample size was markedly different between NGH and GUH cohort. These findings may be possible reasons for this discrepancy for survival analysis.

In conclusion, the expression of ASCT2 is a validated predictive marker for poor prognosis in patients with AC, and is significantly correlated with tumour aggressiveness, cell proliferation, angiogenesis, and mTOR phosphorylation. The inhibition of ASCT2 could be a future therapeutic strategy for lung cancer. However, additional studies are needed to assess the biological significance of inhibiting ASCT2 in human cancer cells.
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![**Immunohistochemical staining of tumour tissue from a 68-year-old male with a pulmonary SQC (A) and a 70-year-old female with a pulmonary AC (B).** ASCT2 exhibited a membranous immunostaining pattern (**A**, score of 4; **B**, score of 3).](bjc201488f1){#fig1}

![**Kaplan--Meier analysis of OS correlated with ASCT2 expression in the NGH and GUH cohorts.** A statistically significant difference in OS was observed between the patients with positive and negative tumour expression of ASCT2 in all patients in the NGH (**A**) and GUH (**D**) cohorts. When OS was separated by histology, a statistically significant difference was identified in patients with AC in the NGH (**B**) and GUH (**E**) cohorts, but not in those with non-AC in NGH (**C**) and GUH (**F**).](bjc201488f2){#fig2}

###### Demographics and clinical characteristics of the patients

  **Variables**              **NGH cohort (*****n*****=104)**   **GUH cohort (*****n*****=204)**   ***P*****-value**
  -------------------------- ---------------------------------- ---------------------------------- -------------------
  **Age**                                                                                          
  ⩽65 years                  31                                 67                                 0.607
  \>65 years                 73                                 137                                 
  **Sex**                                                                                          
  Male                       64                                 119                                0.624
  Female                     40                                 85                                  
  **Smoking**                                                                                      
  Yes                        66                                 126                                0.805
  No                         38                                 78                                  
  **p-Stage**                                                                                      
  I or II                    80                                 159                                0.658
  III or IV                  24                                 41                                  
  **T factor**                                                                                     
  T1-2                       93                                 177                                0.585
  T3-4                       11                                 27                                  
  **N factor**                                                                                     
  N0                         71                                 143                                0.795
  N1-2                       33                                 61                                  
  **Histology**                                                                                    
  AC                         66                                 142                                0.304
  Non-AC                     38                                 62                                  
  **Lymphatic permeation**                                                                         
  Positive                   59                                 87                                 **0.022**
  Negative                   45                                 117                                 
  **Vascular invasion**                                                                            
  Positive                   57                                 72                                 **0.001**
  Negative                   47                                 132                                 
  **ASCT2**                                                                                        
  High                       66                                 101                                **0.022**
  Low                        38                                 103                                 
  **CD98**                                                                                         
  High                       57                                 68                                 **\<0.001**
  Low                        47                                 136                                 
  **Ki-67**                                                                                        
  High                       46                                 90                                 \>0.999
  Low                        58                                 114                                 
  **CD34**                                                                                         
  High                       47                                 69                                 0.062
  Low                        57                                 135                                 
  **p-mTOR**                                                                                       
  High                       41                                 56                                 **0.038**
  Low                        63                                 148                                 

Abbreviations: AC=adenocarcinoma; ASCT2=ASC amino-acid transporter 2; GUH=Gunma University Hospital; NGH=Nishi-Gunma Hospital; non-AC=non-adenocarcinoma; p-mTOR=phosphorylation of mammalian target of rapamycin.

Bold entries show statistically significant difference.

###### Patient\'s demographics according to ASCT2 expression in NGH cohort

                                  **All (*****n*****=104)**   **AC (*****n*****=66)**   **Non-AC (*****n*****=38)**                                         
  -------------------------- ---- --------------------------- ------------------------- ----------------------------- ----- ----- ------------- ----- ----- -----------
  **Age**                                                                                                                                                   
  ⩽65 years                  31   23                          8                         0.182                         18    7     **0.041**     5     1     \>0.999
  \>65 years                 73   43                          30                                                      18    23                  25    7      
  **Sex**                                                                                                                                                   
  Male                       64   46                          18                        **0.035**                     19    12    0.332         27    6     0.279
  Female                     40   20                          20                                                      17    18                  3     2      
  **Smoking**                                                                                                                                               
  Yes                        66   45                          21                        0.209                         17    14    \>0.999       28    7     0.518
  No                         38   21                          17                                                      19    16                  2     1      
  **p-Stage**                                                                                                                                               
  I or II                    80   44                          36                        **0.001**                     20    30    **\<0.001**   24    6     \>0.999
  III or IV                  24   22                          2                                                       16    0                   6     2      
  **T factor**                                                                                                                                              
  T1-2                       93   55                          38                        **0.006**                     27    30    **0.003**     28    8     \>0.999
  T3-4                       11   11                          0                                                       9     0                   2     0      
  **N factor**                                                                                                                                              
  N0                         71   40                          31                        **0.030**                     18    25    **0.009**     22    6     \>0.999
  N1-2                       33   26                          7                                                       18    5                   8     2      
  **Histology**                                                                                                                                             
  AC                         66   36                          30                        **0.019**                     ---   ---   ---           ---   ---   ---
  Non-AC                     38   30                          8                                                                                              
  **Lymphatic permeation**                                                                                                                                  
  Positive                   59   44                          15                        **0.008**                     27    12    **0.006**     17    3     0.438
  Negative                   45   22                          23                                                      9     18                  13    5      
  **Vascular invasion**                                                                                                                                     
  Positive                   57   44                          13                        **0.002**                     17    8     0.126         27    5     0.094
  Negative                   47   22                          25                                                      19    22                  3     3      
  **CD98**                                                                                                                                                  
  High                       57   46                          11                        **\<0.001**                   20    4     **\<0.001**   26    7     \>0.999
  Low                        47   20                          27                                                      16    26                  4     1      
  **Ki-67**                                                                                                                                                 
  High                       46   42                          10                        **\<0.001**                   13    5     0.099         29    5     **0.024**
  Low                        58   24                          28                                                      23    25                  1     3      
  **CD34**                                                                                                                                                  
  High                       47   38                          9                         **0.001**                     22    5     **\<0.001**   16    4     \>0.999
  Low                        57   28                          29                                                      14    25                  14    4      
  **p-mTOR**                                                                                                                                                
  High                       41   30                          11                        0.144                         26    11    **0.006**     4     0     0.559
  Low                        63   36                          27                                                      10    19                  26    8      

Abbreviations: AC=adenocarcinoma; ASCT2=ASC amino-acid transporter 2; NGH=Nishi-Gunma Hospital; non-AC=non-adenocarcinoma; p-mTOR=phosphorylation of mammalian target of rapamycin; p-stage=pathological stage.

Bold entries show statistically significant difference.

###### Univariate and multivariate analysis of overall survival and progression-free survival in NGH cohort

                         **Overall survival**    **Progression-free survival**                                             
  ---------------------- ---------------------- ------------------------------- ---------------------- ---- -------------- ----------------------
  Age                                                        0.959                                              1.640                 
   ⩽65 years             46                              0.513--1.796                                   33   0.884--3.042             
   \>65 years            54                                  0.897                                      55      0.116                 
  Sex                                                        2.322                      1.326                   1.978                 
   Male                  44                              1.284--4.200                0.819--2.174       40   1.130--3.463   2.074 (0.857--5.031)
   Female                66                                **0.005**                    0.255           61    **0.017**            0.106
  Smoking                                                    1.821                      0.898                   1.314                 
   Yes                   47                              1.001--3.299                0.316--2.359       46   0.746--2.313   1.598 (0.646--3.713)
   No                    61                                **0.048**                    0.834           53      0.344              0.302
  p-Stage                                                    6.605                      2.677                   9.022                 
   I or II               62                              2.929--14.89                1.394--5.079       59   4.027--20.21   2.935 (1.574--5.420)
   III or IV             10                               **\<0.001**                 **0.004**         14   **\<0.001**        **\<0.001**
  Histology                                                  1.985                      1.274                   1.388                 
   AC                    57                              1.047--3.763                0.648--2.533       51   0.768--2.507   0.965 (0.509--1.835)
   Non-AC                42                                **0.035**                    0.482           44      0.277              0.915
  Lymphatic permeation                                       2.517                                              2.543                 
   Positive              35                              1.397--4.534                                   34   1.452--4.454             
   Negative              71                                **0.021**                                    67    **0.001**               
  Vascular invasion                                          3.550                                              2.834                 
   Positive              31                              1.968--6.405                                   30   1.619--4.959             
   Negative              78                               **\<0.001**                                   70   **\<0.001**              
  ASCT2                                                      3.137                                              3.183                 
   High                  33                              1.729--5.690            2.753 (1.222--7.071)   30   1.814--5.585   2.861 (1.324--6.896)
   Low                   81                               **\<0.001**                 **0.013**         78   **\<0.001**         **0.009**
  CD98                                                       1.495                                              1.333                 
   High                  47                              0.832--2.686                                   44   0.765--2.325             
   Low                   58                                  0.178                                      54      0.310                 
  Ki-67                                                      1.887                                              1.504                 
   High                  44                              1.045--3.407                                   41   0.861--2.626             
   Low                   60                                **0.035**                                    55      0.151                 
  CD34                                                       1.379                                              1.362                 
   High                  48                              0.763--2.492                                   40   0.778--2.381             
   Low                   56                                  0.287                                      55      0.279                 
  p-mTOR                                                     1.079                                              1.168                 
   High                  50                              0.597--1.948                                   46   0.663--2.506             
   Low                   53                                  0.802                                      49      0.590                 

Abbreviations: 95% CI=95% confidence interval; AC=adenocarcinoma; ASCT2=ASC amino-acid transporter 2; CI=confidence interval; HR=hazard ratio; NGH=Nishi-Gunma Hospital; non-AC=non-adenocarcinoma; p-mTOR=phosphorylation of mammalian target of rapamycin; p-stage=pathological stage.

Bold entries show statistically significant difference.

###### Univariate and multivariate analysis of overall survival and progression-free survival in GUH cohort

                         **Overall survival**    **Progression-free survival**                                             
  ---------------------- ---------------------- ------------------------------- ---------------------- ---- -------------- ----------------------
  Age                                                        0.605                                              0.743                 
   ⩽65 years             76                              0.359--0.992                                   65   0.473--1.167             
   \>65 years            66                                  0.055                                      57      0.197                 
  Sex                                                        1.343                                              1.128                 
   Male                  67                              0.835--2.158            0.922 (0.633--1.316)   59   0.732--1.737   1.130 (0.807--1.553)
   Female                76                                  0.264                      0.665           60      0.585              0.468
  Smoking                                                    1.606                                              1.544                 
   Yes                   65                              0.998--2.584            0.895 (0.610--1.328)   55   0.999--2.384   1.242 (0.871--1.751)
   No                    76                                  0.062                      0.578           67      0.051              0.227
  p-Stage                                                    5.981                                              13.26                 
   I or II               78                              3.213--11.13            3.401 (2.059--5.569)   72   7.147--24.62   2.175 (1.730--2.725)
   III or IV             38                               **\<0.001**                **\<0.001**        16   **\<0.001**        **\<0.001**
  Histology                                                  1.366                                              1.252                 
   AC                    71                              0.809--2.306            1.029 (0.557--1.901)   61   0.780--2.009   0.950 (0.721--1.252)
   Non-AC                66                                  0.323                      0.926           57      0.351              0.715
  Lymphatic permeation                                       3.232                                              3.574                 
   Positive              52                              1.985--5.264                                   39   2.280--5.602             
   Negative              83                               **\<0.001**                                   74   **\<0.001**              
  Vascular invasion                                          3.624                                              3.748                 
   Positive              50                              2.170--6.051                                   37   2.335--6.018             
   Negative              80                               **\<0.001**                                   72   **\<0.001**              
  ASCT2                                                      1.657                                              1.551                 
   High                  61                              1.035--2.654            1.179 (0.911--1.534)   41   1.008--2.388   1.093 (0.868--1.382)
   Low                   77                                **0.035**                    0.209           54    **0.046**            0.447
  CD98                                                       1.541                                              1.710                 
   High                  63                              0.925--2.569                                   48   1.073--2.724             
   Low                   73                                  0.137                                      65    **0.024**               
  Ki-67                                                      1.748                                              1.686                 
   High                  61                              1.083--2.823                                   49   1.091--2.607             
   Low                   76                                **0.031**                                    68    **0.018**               
  CD34                                                       1.876                                              1.642                 
   High                  62                              1.170--3.010                                   51   1.067--2.526             
   Low                   77                                **0.012**                                    68    **0.024**               
  p-mTOR                                                     1.475                                              2.088                 
   High                  61                              0.868--2.505                                   42   1.269--3.437             
   Low                   73                                  0.130                                      66    **0.004**               

Abbreviations: 95% CI=95% confidence interval; AC=adenocarcinoma; ASCT2=ASC amino-acid transporter 2; GUH=Gunma University Hospital; HR=hazard ratio; non-AC=non-adenocarcinoma; p-mTOR=phosphorylation of mammalian target of rapamycin; p-stage=pathological stage.

Bold entries show statistically significant difference.

###### Univariate and multivariate analysis of OS and PFS in AC patients (GUH cohort)

                             **Overall survival**   **Progression-free survival**                                             
  -------------------------- ---------------------- ------------------------------- ---------------------- ---- ------------- ----------------------
  **Age**                                                                                                                     
  ⩽65 years                  78                     0.075                                                  68   0.175          
  \>65 years                 67                                                                            56                  
  **Sex**                                                                                                                     
  Male                       67                     0.267                           0.891 (0.592--1.324)   58   0.509         1.056 (0.732--1.506)
  Female                     74                                                     0.665                  63                 0.766
  **Smoking**                                                                                                                 
  Yes                        63                     **0.046**                       0.898 (0.603--1.354)   52   0.038         1.196 (0.823--1.719)
  No                         77                                                     0.578                  68                 0.343
  **p-Stage**                                                                                                                 
  I or II                    82                     **\<0.001**                     2.186 (1.614--2.967)   75   **\<0.001**   2.175 (1.730--2.725)
  III or IV                  35                                                     **\<0.001**            15                 **\<0.001**
  **Lymphatic permeation**                                                                                                    
  Positive                   46                     **\<0.001**                                            32   **\<0.001**    
  Negative                   86                                                                            78                  
  **Vascular invasion**                                                                                                       
  Positive                   44                     **\<0.001**                                            27   **\<0.001**    
  Negative                   84                                                                            77                  
  **ASCT2**                                                                                                                   
  High                       59                     **0.009**                       1.424 (1.057--1.929)   48   **0.024**     1.205 (0.919--1.583)
  Low                        79                                                     **0.012**              69                 0.177
  **CD98**                                                                                                                    
  High                       61                     0.270                                                  37   **0.021**      
  Low                        73                                                                            66                  
  **Ki-67**                                                                                                                   
  High                       51                     **0.001**                                              37   **0.002**      
  Low                        78                                                                            69                  
  **CD34**                                                                                                                    
  High                       58                     **0.006**                                              43   **0.013**      
  Low                        77                                                                            69                  
  **p-mTOR**                                                                                                                  
  High                       64                     0.243                                                  42   **0.004**      
  Low                        75                                                                            70                  

Abbreviations: 95% CI=95% confidence interval; AC=adenocarcinoma; ASCT2=ASC amino-acid transporter 2; GUH=Gunma University Hospital; HR=hazard ratio; OS=overall survival; PFS=progression-free survival; p-mTOR=phosphorylation of mammalian target of rapamycin; p-stage=pathological stage.

Bold entries show statistically significant difference.

[^1]: These authors contributed equally to this work.
